Beta Bionics, Inc. (NASDAQ:BBNX) Given Consensus Rating of “Moderate Buy” by Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.83.

BBNX has been the topic of a number of recent analyst reports. Robert W. Baird initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective on the stock. Bank of America initiated coverage on shares of Beta Bionics in a research report on Monday, February 24th. They issued a “buy” rating on the stock. Baird R W raised shares of Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Leerink Partnrs raised shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 24th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price objective on the stock.

Beta Bionics Stock Down 0.6 %

Shares of NASDAQ:BBNX opened at $15.69 on Friday. Beta Bionics has a 12 month low of $13.64 and a 12 month high of $24.50.

Insider Transactions at Beta Bionics

In related news, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $17.00 per share, with a total value of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares in the company, valued at $1,003,323. The trade was a 129.92 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The shares were bought at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the transaction, the insider now owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.